 David Wyles
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 57 | 2022 | 654 | 12.420 |
Why?
| | Hepatitis C, Chronic | 30 | 2022 | 151 | 9.240 |
Why?
| | Hepacivirus | 46 | 2024 | 230 | 8.500 |
Why?
| | Hepatitis C | 26 | 2024 | 217 | 8.160 |
Why?
| | Benzimidazoles | 16 | 2020 | 140 | 4.810 |
Why?
| | Drug Resistance, Viral | 17 | 2018 | 98 | 3.640 |
Why?
| | HIV Infections | 28 | 2022 | 2459 | 3.480 |
Why?
| | Coinfection | 15 | 2020 | 119 | 3.460 |
Why?
| | Ribavirin | 15 | 2020 | 88 | 2.620 |
Why?
| | Sulfonamides | 13 | 2020 | 445 | 2.580 |
Why?
| | Sofosbuvir | 16 | 2022 | 52 | 2.550 |
Why?
| | Quinoxalines | 7 | 2019 | 62 | 2.540 |
Why?
| | Fluorenes | 7 | 2020 | 37 | 2.500 |
Why?
| | Liver Cirrhosis | 8 | 2020 | 245 | 2.490 |
Why?
| | Viral Nonstructural Proteins | 9 | 2018 | 59 | 2.180 |
Why?
| | Drug Therapy, Combination | 26 | 2020 | 965 | 2.050 |
Why?
| | Uridine Monophosphate | 5 | 2016 | 15 | 1.900 |
Why?
| | Carbamates | 9 | 2020 | 37 | 1.660 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 208 | 1.610 |
Why?
| | Protease Inhibitors | 10 | 2020 | 102 | 1.540 |
Why?
| | Hepatitis B, Chronic | 3 | 2019 | 18 | 1.510 |
Why?
| | Proline | 11 | 2020 | 71 | 1.430 |
Why?
| | Pyrrolidines | 9 | 2019 | 57 | 1.360 |
Why?
| | Congresses as Topic | 3 | 2021 | 204 | 1.320 |
Why?
| | Hepatitis, Viral, Human | 3 | 2021 | 26 | 1.290 |
Why?
| | Cyclopropanes | 11 | 2020 | 80 | 1.100 |
Why?
| | Genotype | 19 | 2022 | 1882 | 1.090 |
Why?
| | Drug Users | 2 | 2024 | 39 | 1.080 |
Why?
| | Sustained Virologic Response | 10 | 2020 | 33 | 1.030 |
Why?
| | Lactams, Macrocyclic | 10 | 2020 | 47 | 1.020 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 3 | 2017 | 16 | 0.900 |
Why?
| | HIV-1 | 8 | 2020 | 776 | 0.900 |
Why?
| | Virus Replication | 7 | 2012 | 405 | 0.850 |
Why?
| | Disease Eradication | 1 | 2020 | 3 | 0.780 |
Why?
| | Organophosphonates | 4 | 2011 | 94 | 0.760 |
Why?
| | Homosexuality, Male | 2 | 2021 | 166 | 0.750 |
Why?
| | Anti-HIV Agents | 6 | 2020 | 664 | 0.740 |
Why?
| | Humans | 73 | 2024 | 118972 | 0.730 |
Why?
| | Valine | 7 | 2020 | 77 | 0.710 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 2 | 2015 | 18 | 0.620 |
Why?
| | Imidazoles | 2 | 2015 | 232 | 0.600 |
Why?
| | Ritonavir | 6 | 2020 | 70 | 0.600 |
Why?
| | Darunavir | 1 | 2017 | 17 | 0.600 |
Why?
| | Treatment Failure | 5 | 2019 | 341 | 0.590 |
Why?
| | Aminoisobutyric Acids | 5 | 2019 | 8 | 0.580 |
Why?
| | Treatment Outcome | 18 | 2023 | 9342 | 0.570 |
Why?
| | Uracil | 5 | 2020 | 35 | 0.560 |
Why?
| | Anilides | 5 | 2020 | 69 | 0.550 |
Why?
| | Middle Aged | 28 | 2021 | 27617 | 0.550 |
Why?
| | Leucine | 5 | 2019 | 117 | 0.550 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2015 | 260 | 0.550 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 125 | 0.520 |
Why?
| | Male | 37 | 2022 | 57801 | 0.520 |
Why?
| | Biomedical Research | 1 | 2021 | 612 | 0.520 |
Why?
| | Adenine | 4 | 2020 | 223 | 0.510 |
Why?
| | RNA, Viral | 7 | 2015 | 572 | 0.500 |
Why?
| | Viral Load | 7 | 2020 | 419 | 0.490 |
Why?
| | Pyridazines | 1 | 2014 | 50 | 0.480 |
Why?
| | Oligopeptides | 2 | 2013 | 252 | 0.480 |
Why?
| | 2-Naphthylamine | 5 | 2020 | 7 | 0.470 |
Why?
| | Macrocyclic Compounds | 3 | 2019 | 9 | 0.470 |
Why?
| | Adult | 27 | 2023 | 31512 | 0.460 |
Why?
| | Female | 35 | 2022 | 61564 | 0.460 |
Why?
| | Quinolines | 1 | 2014 | 128 | 0.460 |
Why?
| | Purines | 1 | 2014 | 161 | 0.450 |
Why?
| | Liver | 1 | 2021 | 1816 | 0.440 |
Why?
| | Replicon | 3 | 2009 | 15 | 0.440 |
Why?
| | Scavenger Receptors, Class B | 1 | 2012 | 9 | 0.430 |
Why?
| | Disease Management | 1 | 2016 | 571 | 0.420 |
Why?
| | Aged | 16 | 2021 | 19657 | 0.410 |
Why?
| | Retreatment | 2 | 2021 | 71 | 0.380 |
Why?
| | Drug Synergism | 3 | 2008 | 339 | 0.370 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2020 | 224 | 0.330 |
Why?
| | Liver Diseases | 2 | 2016 | 282 | 0.330 |
Why?
| | Dideoxynucleosides | 2 | 2005 | 20 | 0.330 |
Why?
| | Interferon-alpha | 4 | 2013 | 191 | 0.310 |
Why?
| | Cytokines | 1 | 2015 | 1900 | 0.300 |
Why?
| | Global Health | 2 | 2020 | 310 | 0.300 |
Why?
| | Amino Acid Substitution | 2 | 2018 | 276 | 0.290 |
Why?
| | Cytosine | 2 | 2009 | 46 | 0.290 |
Why?
| | Mass Screening | 3 | 2023 | 1052 | 0.260 |
Why?
| | Hepatitis B virus | 2 | 2019 | 25 | 0.260 |
Why?
| | HIV | 2 | 2019 | 210 | 0.250 |
Why?
| | Herpes Simplex | 1 | 2005 | 90 | 0.250 |
Why?
| | Hepatitis | 1 | 2004 | 46 | 0.250 |
Why?
| | Alanine | 2 | 2021 | 102 | 0.250 |
Why?
| | Prevalence | 3 | 2019 | 2326 | 0.230 |
Why?
| | Interferons | 2 | 2015 | 151 | 0.230 |
Why?
| | Young Adult | 10 | 2019 | 10793 | 0.230 |
Why?
| | Mutation, Missense | 3 | 2014 | 300 | 0.210 |
Why?
| | Hospitals | 2 | 2024 | 598 | 0.210 |
Why?
| | Interferon beta-1a | 1 | 2021 | 12 | 0.210 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 51 | 0.200 |
Why?
| | Tenofovir | 2 | 2020 | 200 | 0.200 |
Why?
| | Hepatitis A | 1 | 2021 | 27 | 0.200 |
Why?
| | Hepatitis B | 1 | 2021 | 52 | 0.190 |
Why?
| | Disease Progression | 2 | 2019 | 2490 | 0.190 |
Why?
| | World Health Organization | 1 | 2020 | 107 | 0.190 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 336 | 0.180 |
Why?
| | Polyethylene Glycols | 2 | 2015 | 578 | 0.170 |
Why?
| | Ribosomes | 2 | 2010 | 142 | 0.170 |
Why?
| | Esters | 2 | 2009 | 61 | 0.170 |
Why?
| | CD4 Lymphocyte Count | 2 | 2017 | 267 | 0.170 |
Why?
| | Immunologic Factors | 1 | 2020 | 225 | 0.160 |
Why?
| | Nucleic Acid Conformation | 4 | 2014 | 670 | 0.160 |
Why?
| | Alanine Transaminase | 1 | 2018 | 152 | 0.150 |
Why?
| | DNA, Viral | 1 | 2019 | 356 | 0.150 |
Why?
| | Genes, Viral | 1 | 2016 | 93 | 0.150 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 381 | 0.150 |
Why?
| | Mutation | 2 | 2018 | 3457 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 453 | 0.140 |
Why?
| | Adolescent | 5 | 2022 | 18480 | 0.140 |
Why?
| | Patient Compliance | 1 | 2020 | 537 | 0.140 |
Why?
| | Molecular Structure | 2 | 2008 | 459 | 0.140 |
Why?
| | United States | 8 | 2022 | 12555 | 0.140 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.140 |
Why?
| | Opiate Substitution Treatment | 1 | 2016 | 96 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1945 | 0.130 |
Why?
| | Hospitalization | 1 | 2024 | 1785 | 0.130 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2014 | 18 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2015 | 113 | 0.130 |
Why?
| | Chemokine CXCL10 | 1 | 2014 | 40 | 0.120 |
Why?
| | Chemokines | 1 | 2015 | 230 | 0.120 |
Why?
| | Drug Interactions | 1 | 2015 | 352 | 0.120 |
Why?
| | Viral Proteins | 2 | 2014 | 296 | 0.120 |
Why?
| | Fibrosis | 1 | 2016 | 483 | 0.120 |
Why?
| | Phenylenediamines | 1 | 2013 | 5 | 0.120 |
Why?
| | Prognosis | 2 | 2019 | 3443 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 2 | 2012 | 302 | 0.110 |
Why?
| | Drug Combinations | 3 | 2019 | 291 | 0.110 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.100 |
Why?
| | Mental Disorders | 1 | 2020 | 939 | 0.100 |
Why?
| | Administration, Oral | 1 | 2014 | 756 | 0.100 |
Why?
| | Telemedicine | 1 | 2020 | 664 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2017 | 3171 | 0.100 |
Why?
| | Models, Molecular | 3 | 2012 | 1435 | 0.100 |
Why?
| | Prodrugs | 1 | 2011 | 44 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 245 | 0.100 |
Why?
| | Nucleosides | 1 | 2010 | 26 | 0.100 |
Why?
| | Riboswitch | 1 | 2012 | 58 | 0.100 |
Why?
| | Japan | 2 | 2021 | 97 | 0.090 |
Why?
| | Prospective Studies | 4 | 2023 | 6471 | 0.090 |
Why?
| | Cell Line, Tumor | 2 | 2008 | 2851 | 0.090 |
Why?
| | Biomarkers | 1 | 2020 | 3588 | 0.090 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 736 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.090 |
Why?
| | Drug Design | 1 | 2010 | 160 | 0.090 |
Why?
| | Body Mass Index | 1 | 2017 | 2092 | 0.090 |
Why?
| | Piperidines | 1 | 2010 | 171 | 0.080 |
Why?
| | Cell Line | 2 | 2012 | 2707 | 0.080 |
Why?
| | Phenylthiourea | 1 | 2008 | 5 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1440 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2014 | 745 | 0.080 |
Why?
| | Plasmids | 1 | 2009 | 355 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2009 | 522 | 0.080 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 81 | 0.070 |
Why?
| | Cohort Studies | 4 | 2023 | 5116 | 0.070 |
Why?
| | Luciferases | 1 | 2006 | 143 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2006 | 270 | 0.070 |
Why?
| | Saquinavir | 1 | 2004 | 1 | 0.070 |
Why?
| | Indinavir | 1 | 2004 | 6 | 0.070 |
Why?
| | Nevirapine | 1 | 2004 | 14 | 0.060 |
Why?
| | Nelfinavir | 1 | 2004 | 8 | 0.060 |
Why?
| | Pregnancy | 1 | 2017 | 5690 | 0.060 |
Why?
| | Simplexvirus | 1 | 2005 | 86 | 0.060 |
Why?
| | Drug Labeling | 1 | 2005 | 45 | 0.060 |
Why?
| | Oxazines | 1 | 2004 | 25 | 0.060 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2006 | 227 | 0.060 |
Why?
| | Benzoxazines | 1 | 2004 | 28 | 0.060 |
Why?
| | Lopinavir | 1 | 2004 | 29 | 0.060 |
Why?
| | Alkynes | 1 | 2004 | 56 | 0.060 |
Why?
| | Zidovudine | 1 | 2004 | 77 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 6412 | 0.060 |
Why?
| | Liver Function Tests | 1 | 2004 | 107 | 0.060 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 81 | 0.060 |
Why?
| | Transfection | 1 | 2006 | 888 | 0.060 |
Why?
| | Pyrimidinones | 1 | 2004 | 86 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 244 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2006 | 653 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 1687 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2006 | 527 | 0.050 |
Why?
| | Polyphosphates | 1 | 2022 | 32 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2019 | 12978 | 0.050 |
Why?
| | Singapore | 1 | 2021 | 15 | 0.050 |
Why?
| | Republic of Korea | 1 | 2021 | 26 | 0.050 |
Why?
| | Dried Blood Spot Testing | 1 | 2022 | 68 | 0.050 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 1864 | 0.050 |
Why?
| | Mexico | 1 | 2021 | 165 | 0.050 |
Why?
| | Protein Biosynthesis | 2 | 2014 | 397 | 0.050 |
Why?
| | Raltegravir Potassium | 1 | 2019 | 16 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 57 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 78 | 0.040 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2017 | 11 | 0.040 |
Why?
| | Oxygen | 1 | 2021 | 854 | 0.040 |
Why?
| | Kinetics | 1 | 2020 | 1624 | 0.040 |
Why?
| | Medicaid | 1 | 2020 | 411 | 0.030 |
Why?
| | Incidence | 2 | 2013 | 2424 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 845 | 0.030 |
Why?
| | RNA | 1 | 2022 | 833 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 252 | 0.030 |
Why?
| | Cell-Free System | 1 | 2014 | 49 | 0.030 |
Why?
| | Hepatitis C Antibodies | 1 | 2014 | 10 | 0.030 |
Why?
| | Spain | 1 | 2014 | 34 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1355 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 687 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6561 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 827 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 9000 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2017 | 642 | 0.030 |
Why?
| | Patient Care | 1 | 2014 | 105 | 0.030 |
Why?
| | Withholding Treatment | 1 | 2013 | 67 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2014 | 230 | 0.030 |
Why?
| | Plasma | 1 | 2014 | 224 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2012 | 183 | 0.020 |
Why?
| | Virus Internalization | 1 | 2010 | 41 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1419 | 0.020 |
Why?
| | Ligands | 1 | 2012 | 567 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1308 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 648 | 0.020 |
Why?
| | Magnesium | 1 | 2009 | 150 | 0.020 |
Why?
| | Lamivudine | 1 | 2009 | 59 | 0.020 |
Why?
| | Genome, Viral | 1 | 2009 | 124 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 1901 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3003 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2674 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 2159 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1244 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2025 | 0.010 |
Why?
| | Animals | 2 | 2018 | 33381 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 971 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 4709 | 0.010 |
Why?
| | Mice | 1 | 2009 | 15520 | 0.010 |
Why?
|
|
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|